Long-Term Multilineage Engraftment of Secondary Recipients
| . | % Ly5.1 Cells . | % Ly5.1 Donor Cells . | |||
|---|---|---|---|---|---|
| . | Total . | CD4 . | CD8 . | B220 . | Mac-1/Gr-1 . |
| PB | 21 ± 13 | 15 ± 2 | 5 ± 1 | 33 ± 6 | 54 ± 2 |
| BM | 8 ± 7 | 14 ± 4 | 25 ± 8 | 33 ± 18 | 39 ± 18 |
| Spleen | 15 ± 8 | 23 ± 7 | 12 ± 1 | 60 ± 7 | 13 ± 3 |
| . | % Ly5.1 Cells . | % Ly5.1 Donor Cells . | |||
|---|---|---|---|---|---|
| . | Total . | CD4 . | CD8 . | B220 . | Mac-1/Gr-1 . |
| PB | 21 ± 13 | 15 ± 2 | 5 ± 1 | 33 ± 6 | 54 ± 2 |
| BM | 8 ± 7 | 14 ± 4 | 25 ± 8 | 33 ± 18 | 39 ± 18 |
| Spleen | 15 ± 8 | 23 ± 7 | 12 ± 1 | 60 ± 7 | 13 ± 3 |
BM was harvested from chimeric in utero recipients and injected into irradiated congenic Ly5.2 recipient mice. Six months after transplantation, the PB, BM, and spleen were evaluated for the presence of lineage marker-expressing donor cells. The percentage of donor cells refers to the percentage of total Ly5+ cells that express the donor marker Ly5.1. The percentage of total Ly5.1 donor cells that express a specific lineage marker is also shown (N = 4, mean ± SEM).